VaxEquity

Developing saRNA-based therapeutics and vaccines for unmet medical needs.

[VaxEquity @VaxEquity]

@GeorgeDakwar will be on the Analytical Development Summit panel in Berlin discussing the differences between mRNA vs. SaRNA and how to optimize LNP-saRNA formulations. Learn more:
https://t.co/Iku2Jvr7Ar
#RNA #mRNAtherapeutics #vaccines

[VaxEquity @VaxEquity]

Today is #RNADay, celebrating the vital role RNA plays in sustaining life and improving medicines from COVID vaccines to gene editing. Check out our self-amplifying RNA technology at https://t.co/np3RpNCcEo #Biotech #Lifesciences #drugdiscovery #therapeutics #vaccines

[VaxEquity @VaxEquity]

New #collaboration news: @innovateuk has awarded approximately £700,000 to our exciting new #partnership with @ukCPI to help develop the #manufacturing process of innovative vaccines and treatments: https://t.co/BybhoguG7g

[VaxEquity @VaxEquity]

Our Managing Director Tim Sparey will take our self-amplifying RNA platform (saRNA) on the road to join #BiotechShowcase, one of the biggest #biotech and #lifesciences investor and networking conferences.

Contact [email protected] to connect!

[VaxEquity @VaxEquity]

We’re delighted to be at the Lifestars Awards following the event as finalists in Deal of the Year for our partnership with @AstraZeneca to commercialise a self-amplifying RNA platform (saRNA) and accelerate our innovative Innate Inhibitory Protein (IPP) platform technology.

[VaxEquity @VaxEquity]

Tim Sparey will be attending the @LSXLeaders #InvestivalShowcase, and together with Rob Barber they will be at the Jefferies London Healthcare Conference, to seek out like-minded companies interested in advancing the self-amplifying RNA platform (saRNA) space.

[VaxEquity @VaxEquity]

Our newly appointed Head of Drug Delivery and Formulation George Dakwar will attend the @mrnaconference with @robin_shattock & @KarnyartSamnuan from 8-10 November.

At the event, George, Robin and Kay will be sharing their self-amplifying RNA & mRNA #therapeutics expertise 👇

[International mRNA Health Conference @mrnaconference]

The Program is online!

You can view the program including all sessions on https://t.co/0RqYKZ9ZSP

A great lineup of speakers!!!

[VaxEquity @VaxEquity]

Our technology underpins the next generation of RNA-delivered medicines, enabling #vaccines and a broad range of therapy areas such as #InfectiousDiseases, #oncology and #respiratory. See all the finalists: https://t.co/t6OmIr0HrN

[VaxEquity @VaxEquity]

Proud to be a finalist in @LSXLeaders European Lifestars Awards in the category Deal of the Year for our partnership with @AstraZeneca to commercialise a self-amplifying RNA platform (saRNA) and accelerate our innovative Innate Inhibitory Protein (IPP) platform technology 🥳

[VaxEquity @VaxEquity]

Delighted to be highlighted by @realjacobbell @biopharmadive in excellent feature on #biotech companies making next-gen #RNA technologies as new, longer-lasting, medicines with a broader reach.

See here:
https://t.co/F36wnPLI4X

#lifesciences #vaccines #therapeutics

[VaxEquity @VaxEquity]

Our Director, Dr Mike Watson, will speak at the ExcellGene Symposium in Lausanne on
30 August. The event brings together scientists, investors, and politicians to discuss
#vaccine manufacturing challenges.

See here: https://t.co/zJBdKq4nNb

#biotech #lifesciences

[VaxEquity @VaxEquity]

It’s #RNAday! Take a moment to honour RNA, DNA’s close relative, and a fundamental building block of life as we know it. We’re working on self-amplifying RNA and mRNA therapeutics and vaccines.
See: https://t.co/np3RpNBEOQ

#Biotech #RNA #therapeutics

[VaxEquity @VaxEquity]

We are looking for ambitious & agile scientists to join our team in Cambridge to help create the next generation of self-amplifying RNA #vaccines & #therapeutics. Watch our new film here: https://t.co/WVfrtFLAtO

#recruitment #biotechjobs #biotech

[VaxEquity @VaxEquity]

Tim Sparey, our Managing Director, will be at the world’s largest bio-industry partnering event, #BIO2022.
Connect with us to learn more about our self-amplifying #RNA platform.
Link to the event: https://t.co/vZjooPbeXZ

[VaxEquity @VaxEquity]

We are looking for an exceptional Project Director to lead our Project and Program Management activities. Come and join us at the beginning of our exciting, scientific journey. Apply here: https://t.co/bFbAQGxGAR
#biotech #saRNA #RNA

[VaxEquity @VaxEquity]

We are looking for an exceptional Senior Scientist who will be responsible for the design, research, and development of RNA formulations. Apply here: https://t.co/qVg5ynOoYh
#biotech #saRNA #RNA

[VaxEquity @VaxEquity]

We are looking to recruit an experienced and motivated RNA Development Scientist who will play a key role in developing our technology and establishing a pipeline of new vaccines and therapeutics. Apply here: https://t.co/pjCng86N4v #saRNA #RNA

[VaxEquity @VaxEquity]

We are expanding at @CamSciencePark with 2,000 sq ft of lab space and welcome our new team members Rob Barber, Senior Director, Alliance Management and Conor Woolfson as Finance Director.

Read the full release on our revamped new website: https://t.co/JM6nHqu2jV

[VaxEquity @VaxEquity]

Our Managing Director, Tim Sparey, will be attending the 22nd Bio€quity Europe 2022 in Milan, Italy from the 16th to the 18th of May 2022.The event is organised by @BioCentury Inc. and @EBDgroup

#saRNA #BioTech #conference #BioEquity

[VaxEquity @VaxEquity]

Great to see recent news featured in @ScienceMagazine of solid top line Phase III results for @ArcturusRx #COVID19 vaccine trial. This trial showed 95% efficacy in preventing severe disease, which validates #saRNA #vaccines.